A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 500 participants.

Also called NCT07940777

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07940777
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07940777. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-29 (anticipated); primary completion 2029-07-21 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)
Acronym
SOLSTICE-HCM
Condition
Non-obstructive Hypertrophic Cardiomyopathy
Intervention (Drug)
Mavacamten
Intervention (Other)
Placebo
Lead sponsor
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct07940777
Content hash
f36bba4df4b3007451cd67c7a71dbd30b75ab02231f9974ecfee5c6f099de2b0